Table 1_Megestrol acetate in the management of cancer cachexia: a prospective quasi-experi

A prospective quasi-experimental study of 97 patients with cancer cachexia, allocated to control or megestrol acetate groups over a 2-month intervention period. The dataset includes primary endpoints like weight, BMI, skeletal muscle mass, and fat mass, plus secondary endpoints covering inflammatory markers, immune parameters, cancer-related fatigue, and quality of life. Authored by Xiaoting Zhong and last updated on 2026-04-21.

Use Cases

• Analyze the efficacy of megestrol acetate on nutritional indices like body weight, BMI, and fat mass.
• Model the relationship between inflammatory markers (CRP, IL-6, TNF-α) and changes in patient-reported fatigue scores.
• Compare skeletal muscle mass preservation between treatment and control groups over the 2-month study period.
• Assess the impact of the intervention on quality of life (QOL) scores across different patient subgroups.

Strengths

• Includes data from 97 patients, providing a clear sample size for analysis.
• Captures multi-dimensional endpoints: nutritional, inflammatory, immune, fatigue, and QOL metrics.
• Prospective study design with a 2-month intervention period for longitudinal assessment.
• Reported no drug-related adverse events, indicating good tolerability data.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The study is non-randomized (quasi-experimental), which may introduce selection bias.

Provenance

Source

figshare, author Xiaoting Zhong

Collection Method

Prospective, non-randomized clinical study.

Time Range

Intervention period of 2 months (specific dates not provided).

Freshness

Last updated 2026-04-21 04:22:23; freshness should be verified.